about us

the Kode Group

Kode Biotech is the holder and parent of companies that license Kode Technology for different sectors and uses. The group also includes GlycoNZ, which supplies a broad range of glycoconjugate research probes, including FSL constructs.

Kode Group companies: who does what

Parent company

Kode Biotech

Owns Kode Technology and its intellectual property. Designs and makes FSL constructs, and sells them worldwide through GlycoNZ.

Supply subsidiary

GlycoNZ

Sells research FSL constructs and glycoconjugates through glyconz.com and Merck MilliporeSigma.

Supply subsidiary

Kode Biotech Materials

Supplies FSL constructs at large scale, quality-assured, direct to pharmaceutical companies.

Spin-out company

Kode Veterinary Sciences

Develops Kv9, a Gen 3 KIE, for veterinary cancer.

Spin-out company

Kode Agalimmune

Develops AGI-134, a Gen 2 KIE, for human cancer, and holds the alpha(Gal)OV-IO oncolytic virus asset.

Spin-out company

KodeRx

Develops K5K, a Gen 3 KIE, for human cancer, with a focus on affordable and accessible products.

Future spin-out companies

New applications

Kode Biotech develops each major application of Kode Technology through its own company. Further spin-out companies may be formed as new applications mature.

Kode Technology resources, including the Technical Manual and Stephen Henry's DSc thesis, are free on the Downloads page. The research, manufacturing, and sales and distribution partners the group works with are on the Our Partners page.

meet our people

Work with us: partner with kode

Licensing, research collaboration and custom FSL constructs.